Browse > Article
http://dx.doi.org/10.7314/APJCP.2013.14.7.4049

Estrogen Receptor α Roles in Breast Cancer Chemoresistance  

Xu, Chao-Yang (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Jiang, Zhi-Nong (Department of Pathology, Sir Run Run Shaw Hospital, Zhejiang University College of Medicine)
Zhou, Ying (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Li, Jia-Jia (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Huang, Li-Ming (Department of Breast and Thyroid Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.14, no.7, 2013 , pp. 4049-4052 More about this Journal
Abstract
Resistance to chemotherapy treatment, which may lead to limited efficacy of systemic therapy in breast cancer patients, is multifactorial. Among the mechanisms of resistance to chemotherapy treatment, there are those closely related to estrogen receptor ${\alpha}$, P-glycoprotein, multidrug resistance-related protein, glutathione S-transferase pi and topoisomerase-II. $ER{\alpha}$ is ligand-activated transcription factor that regulates gene expression and plays a critical role in endocrine signaling. In previous preclinical and clinical studies, positive $ER{\alpha}$ expression in breast cancer cells was correlated with decreased sensitivity to chemotherapy. This article reviews current knowledge on the predictive value of $ER{\alpha}$ with regard to response to chemotherapy. Better understanding of its role may facilitate patient selection of therapeutic regimens and lead to optimal clinical outcomes.
Keywords
Estrogen receptor ${\alpha}$; chemoresistance; breast cancer; Fulvestrant;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, et al (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors, a GINECO study. J Clin Oncol, 30, 2718-24.   DOI
2 Bailey ST, Shin H, Westerling T, et al (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A, 109, 18060-5.   DOI
3 Bailey ST, Shin H, Westerling T, et al (2012). Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A, 109, 18060-5.   DOI
4 Chen D, Hackl W, Ortmann O, et al (2004). Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs, 15, 55-61.   DOI   ScienceOn
5 Cohen I (2008). Aromatase inhibitors and the endometrium. Maturitas, 59, 285-92.   DOI   ScienceOn
6 Coleman RE, Body JJ, Gralow JR, et al (2008). Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies. Cancer Treat Rev, 34, S31-42.   DOI   ScienceOn
7 Donmez Y, Akhmetova L, Iseri OD, Kars MD, Gunduz U (2011). Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicinresistant MCF-7 cells. Cancer Chemother Pharmacol, 67, 823-8.   DOI
8 Dziadyk JM, Sui M, Zhu X (2004). Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest. Anticancer Res, 24, 27-36.
9 Early Breast Cancer Trialists Collaborative Group (EBCTCG), Clarke M, Coates AS, et al (2008). Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer, patient-level metaanalysis of randomised trials. Lancet, 371, 29-40.   DOI   ScienceOn
10 Fisher B, Dignam J, Bryant J, et al (1996). Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst, 88, 1529-42.   DOI   ScienceOn
11 Fleeman N, Martin Saborido C, Payne K, et al (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen, a systematic review. Health Technol Assess, 15, 1-102.
12 Geisler J, Smith I, Miller W (2012). Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients. J Steroid Biochem Mol Biol, 131, 93-100.   DOI   ScienceOn
13 Gilani RA, Kazi AA, Shah P, et al (2012). The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat, 135, 681-92.   DOI
14 Karroum A, Mirshahi P, Faussat AM, et al (2012). Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. Eur J Pharmacol, 685, 1-7.   DOI   ScienceOn
15 Goncalves R, Ma C, Luo J, et al (2012). Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol, 9, 223-9.   DOI
16 Jeong JH, Jung SY, Park IH, et al (2012). Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. Invest New Drugs, 30, 408-16.   DOI
17 Jiang Z, Guo J, Shen J, et al (2012). The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells. J Exp Clin Cancer Res, 31, 42.   DOI
18 Kemp Z, Jones A (2011). A shift in the treatment of hormone receptor and human epidermal growth factor receptor 2-positive metastatic breast cancer. Adv Ther, 28, 603-14.   DOI
19 Larsen MS, Bjerre K, Giobbie-Hurder A, et al (2012). Prognostic value of Bcl-2 in two independent populations of estrogen receptor positive breast cancer patients treated with adjuvant endocrine therapy. Acta Onco, 51, 781-9.   DOI   ScienceOn
20 Lips EH, Mulder L, de Ronde JJ, et al (2012). Neoadjuvant chemotherapy in ER+ HER2- breast cancer, response prediction based on immunohistochemical and molecular characteristics. Breast Cancer Res Treat, 131, 827-36.   DOI   ScienceOn
21 Lv M, Li B, Li Y, et al (2011). Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China. Asian Pac J Cancer Prev, 12, 2411-7.
22 Mutoh K, Tsukahara S, Mitsuhashi J, et al (2006). Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci, 97, 1198-204.   DOI   ScienceOn
23 Petit T, Wilt M, Velten M, et al (2010). Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer. Breast Cancer Res Treat, 124, 387-91.   DOI
24 Natarajan K, Xie Y, Baer MR, et al (2012). Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol, 83, 1084-103.   DOI   ScienceOn
25 Oliveira CA, Nie R, Carnes K, et al (2003). The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules. Reprod Biol Endocrinol, 1, 75.   DOI   ScienceOn
26 Osako T, Nishimura R, Okumura Y, et al (2012). Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. Exp Ther Med, 3, 66-71.
27 Precht LM, Lowe KA, Atwood M, et al (2010). Neoadjuvant chemotherapy of breast cancer, tumor markers as predictors of pathologic response, recurrence, and survival. Breast J, 16, 362-8.
28 Puhalla S, Bhattacharya S, Davidson NE (2012). Hormonal therapy in breast cancer, a model disease for the personalization of cancer care. Mol Oncol, 6, 222-36.   DOI   ScienceOn
29 Romero A, Mart n M, Cheang MC, et al (2011). Assessment of Topoisomerase II ${\alpha}$ status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol, 178, 1453-60.   DOI   ScienceOn
30 Romero A, Mart n M, Oliva B, et al (2012). Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. Ann Oncol, 23, 1750-6.   DOI   ScienceOn
31 Tabuchi Y, Matsuoka J, Gunduz M, et al (2009). Resistance to paclitaxel therapy is related with Bcl-2 expression through an estrogen receptor mediated pathway in breast cancer. Int J Oncol, 34, 313-9.
32 Saylam B, Efesoy O, Cayan S (2011). The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril, 95, 809-11.   DOI   ScienceOn
33 Shi R, Li W, Zhang X, et al (2011). A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. Eur J Pharmacol, 669, 38-44.   DOI   ScienceOn
34 Sui M, Huang Y, Park BH, et al (2007). Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res, 67, 5337-44.   DOI   ScienceOn
35 Tokuda E, Seino Y, Arakawa A, et al (2012). Estrogen receptor-_directly regulates sensitivity to paclitaxel in neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat, 133, 427-36.   DOI   ScienceOn
36 Walker CH, Drew BA, Antoon JW (2012). Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer, recent perspectives. Cancer Invest, 30, 135-48.   DOI   ScienceOn
37 Wang L, Jiang Z, Sui M, et al (2009). The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens, a case control study. BMC Cancer, 9, 226.   DOI   ScienceOn
38 Wu L and Tannock IF (2005). Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res, 11, 8195-200.   DOI   ScienceOn
39 Xu C, Li J, Lu Y, et al (2012). Estrogen receptor ${\alpha}$ and hedgehog signal pathway developmental biology of gastric adenocarcinoma. Hepatogastroenterology, 59, 1319-22.